Celltrion Pharm announced on the 14th that its third-quarter sales reached approximately 128.1 billion KRW, marking a 37.2% increase compared to the same period last year, setting a new record for quarterly earnings.
During the same period, operating profit rose by 108.3% to approximately 13.6 billion KRW, with an operating margin of 10.7%. The accumulated figures for the third quarter showed sales of around 342.3 billion KRW and an operating profit of about 26.8 billion KRW. Despite challenges such as workforce expansion and increased R&D expenses, Celltrion Pharm focused on improving operating profits by reducing sales commissions, driven by strong performance in major products and the impact of new products.
In the chemical business segment, their leading liver drug, “Godex,” recorded sales of about 18.2 billion KRW. The antihypertensive drug “Dilatrend Tab,” which began full-scale sales in the second quarter, contributed to growth with sales of approximately 12.8 billion KRW.
In the biosimilar business segment, the self-injection autoimmune disease treatment “Remsima SC” saw a 60% increase in patients prescribed compared to the same period last year. The breast and gastric cancer treatment “Herzuma” and the blood cancer treatment “Truxima” performed well. Meanwhile, sales of the autoimmune disease treatment “Uplima” and the anticancer drug “Vegzelma,” both launched last year, became visible, achieving quarterly sales of about 21.7 billion KRW.
Looking ahead, Celltrion Pharm plans to expand sales by ensuring new products settle in the market and increasing production volumes. The company aims to secure differentiated competitiveness through R&D investment and propel growth to become one of the top five pharmaceutical companies in Korea by 2030.
Initially, Celltrion Pharm intends to focus on expanding performance by enhancing marketing of three new biosimilar products that entered the market last September—the autoimmune disease treatment “Stelletma,” the ophthalmic disease treatment “Idenzel,” and the allergic asthma treatment “Omriclo.”
Cooperating with partners like Dong-A Pharmaceutical and Daewoong Pharmaceutical, who have joint sales agreements, Celltrion Pharm aims to ensure a stable supply of high-quality therapeutic products to the market.
The company also plans to reinforce profitability by completing internal production of major acquired products, such as the diabetes treatment “Nesina” and the antihypertensive treatment “Edarbi,” with current production and supply proceeding smoothly.
The Cheongju plant’s PFS (pre-filled syringe) production facility, having completed major GMP certifications from key global regulatory agencies, is now in full-capacity production mode. As they begin full-scale production of major products like “Zimfentra” and “Uplima,” they have recorded a 577% increase in sales compared to the same period last year.
In R&D, Celltrion Pharm, together with Celltrion, is focusing on developing improved new combination drugs for diabetes and hypertension treatments that increase administration convenience. The company is preparing for domestic approval procedures for a three-drug combination for hypertension and dyslipidemia, with growth expected from expanded follow-up products.
A representative from Celltrion Pharm stated, “The third quarter’s robust sales performance was driven by balanced growth in major products,” adding, “We will continue to solidify core product performance while boosting new business and R&D innovation to achieve the Vision 2030 targets.”